Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of intravenously delivered
mesenchymal steml cells (MSC) in one of two fixed dosing regimens at two time points in
patients with chronic kidney disease.